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ABSTRACT
Familial hyperekplexia, also called startle disease, is a rare neurological disorder characterized by excessive startle responses to 
noise or touch. It can be associated with serious injury from frequent falls, apnea spells, and aspiration pneumonia. Familial hy-
perekplexia has a heterogeneous genetic background with several identified causative genes; it demonstrates both dominant and 
recessive inheritance in the α1 subunit of the glycine receptor (GLRA1), the β subunit of the glycine receptor and the presynaptic 
sodium and chloride-dependent glycine transporter 2 genes. Clonazepam is an effective medical treatment for hyperekplexia. 
Here, we report genetically confirmed familial hyperekplexia patients presenting early adult cautious gait. Additionally, we re-
view clinical features, mode of inheritance, ethnicity and the types and locations of mutations of previously reported hyperek-
plexia cases with a GLRA1 gene mutation.
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Hyperekplexia, or startle disease, is an uncommon nonepi-
leptic disorder classically characterized by exaggerated startle 
responses to unexpected stimuli. It can occur as a hereditary 
disorder and is typically caused by a mutation in the alpha 1 
subunit of the glycine receptor (GLRA1) gene.1 The major form 
of hyperekplexia refers to the type that occurs in neonates, who 
have hypertonia or stiffness that tends to resolve over time.2 We 
report a new case of genetically confirmed familial hyperek-
plexia caused by GLRA1 mutation and systematically review 
the phenotypes reported in the literature. 
CASE REPORT
A 20-year-old woman visited the neurology clinic for gener-
alized stiffness and frequent falling episodes secondary to tac-
tile stimuli. She was born at term, and her antenatal and birth 
history were not remarkable. There was no developmental de-
lay or neurologic deficit; however, her parents had noticed sud-
den falling events since she was five years old. In response to 
unexpected tactile stimulation, she felt her body become rigid 
for a few seconds, which resulted in injurious falling down 
events with spared consciousness. She usually kept indoors 
and walked cautiously in order to avoid unexpected falling ac-
cidents. In childhood, the frequency of her falls was approxi-
mately four or five times per year, but after her teenage years, 
the frequency decreased to once or twice per year. She remem-
bered that drinking alcohol ameliorated the symptoms. Her fa-
ther and older sister had similar symptoms (Figure 1A). On 
physical examination, she had numerous scars on her forehead 
from previous falling accidents. Apart from cautious gait, her 
neurological examination was normal. Brain MRI and EEG 
were not remarkable.
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Whole exome sequencing with genomic DNA 
extracted from peripheral blood identified a het-
erozygous missense mutation c.896G>A (reference 
sequence: NM_001146040.1) in GLRA1. No muta-
tions were found in other genes known to cause fa-
milial hyperekplexia, such as GLRB, SLC6A5, GPHN, 
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Figure 1. A pedigree of a Korean family with hyperekplexia (A). An arrow indicates the proband. Selected sequences 
from GLRA1 exon 7 indicating the c.896G>A mutation using reverse primers (B). The results of systematic review of 
the literature regarding hyperekplexia caused by GLRA1 mutation are shown with respect to percentage of clinical 
features (C) and types and locations of mutations with mode of inheritance (D) and ethnicity (E). In the percentage 
bar graph (C), blue refers to present, red refers to absent, and green means not available. Numbers beside the 
bars in graph D represent number of cases with the specified mutation. NA: not available, AD: autosomal domi-
nant, AR: autosomal recessive.
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and ARHGEF9. The change in the patient’s GLRA1 
sequence alters the arginine codon at 299 to a gly-
cine codon (p.Arg299Gln). This mutation was con-
firmed by Sanger sequencing (Figure 1B). The same 
mutation was also found in her sister, who was symp-
tomatic; however, we could not perform a genetic 
study on her parents. Clonazepam was administered 
at a dose of 0.5 mg per day, which resulted in an im-
provement in the startle response. 
DISCUSSION
Hyperekplexia, known as a hereditary startle dis-
ease, is characterized by an exaggerated startle re-
sponse and neonatal hypertonia. This disorder is a 
rare neurogenetic condition, but it is potentially 
treatable.1 The symptom spectrum can vary from 
an exaggerated startle response to infantile apnea 
spells and even injurious falls. The disease can be 
accompanied by abdominal hernia, hip dislocation 
and developmental delay.2 A previous case study 
reported a possible association with sudden infant 
death syndrome.3 In patients with hyperekplexia, no 
abnormalities are observed on routine blood tests, 
urinalysis, brain imaging studies, or EEG.1 Hyper-
ekplexia could be misdiagnosed as epilepsy, cere-
bral palsy, anxiety disorder, or conversion disorder 
and therefore can be mistreated. Early diagnosis and 
treatment are important, as they not only prevent 
injuries but may also influence the quality of life of 
a patient. 
To conduct a systematic review of the literature re-
garding hyperekplexia cases caused by mutation in 
the GLRA1 gene, we retrieved articles from the 
PubMed database using the keywords “Hyperek-
plexia AND GLRA1, English” and “Hyperekplexia 
AND case, English”. The references used in this sys-
tematic review are listed in the supplementary in-
formation. Clinical features, ethnicity, types and lo-
cations of mutations and mode of inheritance, as 
obtained from the retrieved literature, are summa-
rized in Table 1. Most patients showed neonatal hy-
pertonia (76%) and an exaggerated startle response 
(73%). Most patients (64 out of 66 cases with the 
nose-tapping test) exhibited a hyperactive brain-
stem reflex, which was found with the nose-tapping 
test. Exaggerated head retraction reflexes in response 
to the nose-tapping test indicate exaggerated brain-
stem reflexes and provide an important clue to di-
agnose hyperekplexia. The patients also suffered 
from severe complications, such as developmental 
delay (16.8%) and apnea spells (20.7%). External ab-
normalities, such as umbilical (13.9%) and inguinal 
hernia (11.2%), hip dislocation (6.8%) and club foot 
(1.9%), were not uncommonly observed (Figure 1C). 
These findings are consistent with a previous case 
series that is not included in our analysis.4 Clinical 
features that helped differentiate hyperekplexia 
from epilepsy included unexpected stimulus-induc-
ing falling accidents, short episodes lasting only a 
few seconds, and spared consciousness, with no oth-
er abnormal movements accompanying the event. 
Cautious gait, face lacerations and family history 
may be helpful for differentiating hyperekplexia 
from conversion disorder. Frequent falls were ob-
served in 39.8% of cases for which information was 
available, and cautious gait was reported infrequent-
ly (4%). Data regarding falls and gait might have 
been biased by patients’ age, and therefore, there is 
a potential for missed information. Six out of 161 
reviewed patients exhibited a wide-based and stiff 
gait due to considerable fear of an unexpected fall-
ing event, and two patients lacked confidence in out-
door environments, resulting in impaired social be-
havior. Presentation of a cautious gait resulting from 
unexpected falling episodes might be an indication 
of hyperekplexia. Clonazepam, which enhances GA-
BA-gated chloride channel function and presum-
ably compensates for defective glycine-gated chlo-
ride channel function, has been considered the first 
choice for the treatment of hyperekplexia. Antiepi-
leptic drugs, including carbamazepine, phenytoin, 
valproate, and vigabatrin, have also been used for 
treatment.1 In this review, 60 out of 70 cases (85.7%) 
showed good response to clonazepam, which is 
similar to a previous study.4
Among genes causing familial hyperekplexia, 
GLRA1 is the most common causative gene, ac-
counting for 80% of hereditary cases.5,6 Our patients 
carried a heterozygous mutation, p.Arg299Gln, 
which was inherited in an autosomal dominant fash-
ion. Missense mutation of the arginine at codon 
299, which was previously reported as codon 271, 
is the most common (Table 1, Figure 1D). Both au-
tosomal dominant and recessive inheritance have 
been reported in familial hyperekplexia caused by 
GLRA1 mutation. Our analysis showed that domi-
nant inheritance (73.9%) was 3-fold more common-
56
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ly reported than recessive inheritance (26.1%). In-
terestingly, most dominantly inherited mutations 
were located between codons 290–300 of the GLRA1 
gene (Figure 1D). Distribution of ethnicity in the re-
viewed hyperekplexia cases was Caucasian (42%), 
Asian (33%), Turkish (14%), Arabic (8%), and Afri-
can (3%) (Figure 1E). In a genotype-ethnicity cor-
relation, 8 Asian families (including isolated cases) 
and 7 Caucasian families demonstrated the p.Arg-
299Gln mutation of the GLRA1 gene. These find-
ings support the notion that the Arg299 amino acid 
site is vulnerable to hyperekplexia in ethnically dis-
parate cases.7
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